Not available
Quote | BeiGene Ltd. (NASDAQ:BGNE)
Last: | $162.54 |
---|---|
Change Percent: | -0.34% |
Open: | $163.82 |
Close: | $162.54 |
High: | $165.5 |
Low: | $161.7 |
Volume: | 101,477 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | BeiGene Ltd. (NASDAQ:BGNE)
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | BeiGene Ltd. (NASDAQ:BGNE)
Subject | By | Source | When |
---|---|---|---|
BGNE having a nice bounce and a good, | MiamiGent | investorshub | 07/05/2023 7:28:03 PM |
Thoughts on where this is headed? | StockLearner2011 | investorshub | 07/03/2023 9:49:33 PM |
Found an interesting article | luke424 | investorshub | 06/30/2023 1:45:08 AM |
$BGNE must see | StockLearner2011 | investorshub | 06/28/2023 1:49:55 AM |
here we go bulls news is here | StockLearner2011 | investorshub | 06/22/2023 3:12:55 PM |
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...